Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Incyte Corporation (INCY) Price & Performance

Dell Technologies IncTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Incyte Corporation — how do they compare? Dell Technologies Inc trades at $464.62 (market cap $284.93B), while Incyte Corporation trades at $121.25 (market cap $24.54B). The key difference: Dell Technologies Inc is far larger — about 11.6× Incyte Corporation's market cap, and Dell Technologies Inc pays a 0.57% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

DELLINCY
Market Cap
$284.93B$24.54B
Sector
TechnologyHealth
52-Week High
$467.27$129.93
52-Week Low
$111.10$81.61
Enterprise Value
$304.51B$20.04B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.

The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.

Incyte Corporation

INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.

Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY